Vaccine Therapy and GM-CSF in Treating Patients With Recurrent or Metastatic Melanoma
Completed · Phase 2
Conditions studied: Melanoma (Skin)
In brief
RATIONALE: Vaccines made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor cells. Colony-stimulating factors, such as GM-CSF, increase the number of white blood cells and platelets found in bone marrow or peripheral blood. Giving vaccine therapy together with GM-CSF may be an effective treatment for melanoma. PURPOSE: This randomized phase II trial is studying two different vaccine therapy regimens to compare how well they work when given together with GM-CSF in treating patients with recurrent or metastatic melanoma.
Key facts
- Study ID
- NCT00436930
- Run by
- Hoag Memorial Hospital Presbyterian
- People needed
- 200
- Starts
- 2006-12-01
- Expected to finish
- 2012-10-01
- Last updated by the study team
- 2014-01-10
Who can join
Age: 16 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Hoag Cancer Institute at Hoag Memorial Hospital Presbyterian — Newport Beach, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.